Coherus Oncology, Inc.CHRSNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank8
3Y CAGR-41.8%
5Y CAGR-18.2%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-41.8%/yr
vs +115.7%/yr prior
5Y CAGR
-18.2%/yr
Recent deceleration
Acceleration
-157.5pp
Decelerating
Percentile
P8
Near historical low
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $13.81M | -88.2% |
| 2024 | $117.55M | -26.1% |
| 2023 | $158.99M | +126.9% |
| 2022 | $70.08M | +21.7% |
| 2021 | $57.59M | +52.9% |
| 2020 | $37.67M | +120.6% |
| 2019 | $17.08M | +427.9% |
| 2018 | $3.23M | -98.0% |
| 2017 | $160.53M | -36.9% |
| 2016 | $254.44M | - |